Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou
{"title":"[COBE2991®结束：每种类型的细胞治疗产品的制备有哪些替代品？](SFGM-TC)]。","authors":"Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou","doi":"10.1016/j.bulcan.2025.04.008","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this article is to discuss alternatives to COBE2991® (Terumo BCT©) for the preparation of cell therapy products, in view of its planned cessation of commercialization in 2025. Cell therapy units need to find alternative methods in the face of regulatory restrictions and equipment obsolescence. Currently, COBE2991® (Terumo BCT©) is widely used in France, but its replacement will require multiple validations and adjustment of practices, as there is no single equivalent equipment. Recommendations for harmonizing these practices were discussed at a specific workshop in September 2024, following a survey of 25 French-speaking cell therapy centers.</p>","PeriodicalId":93917,"journal":{"name":"Bulletin du cancer","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[End of COBE2991®: What alternatives are available for the preparation of each type of cell therapy products? (SFGM-TC)].\",\"authors\":\"Justine Nasone, Carina Alves Goncalves, Caroline Ballot, Ulrick Birba, Maxime Bouabdelli, Lucille Capin, Alexandra Clerc, Marie Agnès Guerout Vérité, Khadija Hajjout, Antoine Haquette, Xavier Lafarge, Elisa Magrin, Florence Pierre, Eden Schwartz, Boris Calmels, Hélène Rouard, Leonardo Magro, Valérie Mialou\",\"doi\":\"10.1016/j.bulcan.2025.04.008\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The aim of this article is to discuss alternatives to COBE2991® (Terumo BCT©) for the preparation of cell therapy products, in view of its planned cessation of commercialization in 2025. Cell therapy units need to find alternative methods in the face of regulatory restrictions and equipment obsolescence. Currently, COBE2991® (Terumo BCT©) is widely used in France, but its replacement will require multiple validations and adjustment of practices, as there is no single equivalent equipment. Recommendations for harmonizing these practices were discussed at a specific workshop in September 2024, following a survey of 25 French-speaking cell therapy centers.</p>\",\"PeriodicalId\":93917,\"journal\":{\"name\":\"Bulletin du cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin du cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.bulcan.2025.04.008\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin du cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bulcan.2025.04.008","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
